Seres Therapeutics (NASDAQ:MCRB) Downgraded to “Sell” Rating by Wall Street Zen

Wall Street Zen cut shares of Seres Therapeutics (NASDAQ:MCRB) from a hold rating to a sell rating in a report issued on Saturday.

Separately, Weiss Ratings reissued a “sell (d)” rating on shares of Seres Therapeutics in a research report on Monday, December 29th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus price target of $14.33.

Seres Therapeutics Price Performance

Shares of MCRB opened at $8.47 on Friday. The company has a 50-day simple moving average of $15.06 and a two-hundred day simple moving average of $16.80. The firm has a market capitalization of $76.65 million, a PE ratio of -2.37 and a beta of 0.22. Seres Therapeutics has a one year low of $6.53 and a one year high of $29.98.

Hedge Funds Weigh In On Seres Therapeutics

Hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC grew its position in Seres Therapeutics by 1.4% during the 4th quarter. Geode Capital Management LLC now owns 86,142 shares of the biotechnology company’s stock valued at $1,282,000 after purchasing an additional 1,160 shares during the last quarter. State Street Corp raised its holdings in Seres Therapeutics by 14.0% in the fourth quarter. State Street Corp now owns 33,901 shares of the biotechnology company’s stock worth $504,000 after buying an additional 4,170 shares during the last quarter. Vontobel Holding Ltd. lifted its stake in shares of Seres Therapeutics by 4.8% in the fourth quarter. Vontobel Holding Ltd. now owns 103,234 shares of the biotechnology company’s stock worth $1,536,000 after buying an additional 4,723 shares in the last quarter. Bank of America Corp DE grew its holdings in shares of Seres Therapeutics by 2,772.6% during the third quarter. Bank of America Corp DE now owns 5,343 shares of the biotechnology company’s stock valued at $103,000 after buying an additional 5,157 shares during the last quarter. Finally, Goldman Sachs Group Inc. purchased a new stake in shares of Seres Therapeutics during the fourth quarter valued at approximately $213,000. Institutional investors own 59.34% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.